Bardoxolone Methyl (BioDeep_00000783095)
代谢物信息卡片
Bardoxolone Methyl
化学式: C32H43NO4 (505.31919180000006)
中文名称: 甲基巴多索隆
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)OC)C
InChI: InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1
描述信息
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C471 - Enzyme Inhibitor > C29574 - Nitric Oxide Synthase Inhibitor
C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:177406
- KEGGdrug: D09585
- PubChem: 400769
- DrugBank: DB05983
- ChEMBL: CHEMBL1762621
- CAS: 218600-53-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Kristiana M Amirova, Petya A Dimitrova, Milena N Leseva, Ivanka K Koycheva, Albena T Dinkova-Kostova, Milen I Georgiev. The Triterpenoid Nrf2 Activator, CDDO-Me, Decreases Neutrophil Senescence in a Murine Model of Joint Damage.
International journal of molecular sciences.
2023 May; 24(10):. doi:
10.3390/ijms24108775. [PMID: 37240121] - Xiaokai Wang, Jun Chen, Hongyan Tie, Wei Tian, Yanli Zhao, Luying Qin, Siyan Guo, Qiufang Li, Chen Bao. Eriodictyol regulated ferroptosis, mitochondrial dysfunction, and cell viability via Nrf2/HO-1/NQO1 signaling pathway in ovarian cancer cells.
Journal of biochemical and molecular toxicology.
2023 Apr; ?(?):e23368. doi:
10.1002/jbt.23368. [PMID: 37020356] - Yoshifumi Kurosaki, Akemi Imoto, Fumitaka Kawakami, Motoshi Ouchi, Asuka Morita, Masanori Yokoba, Tsuneo Takenaka, Takafumi Ichikawa, Masato Katagiri, Rikke Nielsen, Naohito Ishii. In vitro study on effect of bardoxolone methyl on cisplatin-induced cellular senescence in human proximal tubular cells.
Molecular and cellular biochemistry.
2022 Mar; 477(3):689-699. doi:
10.1007/s11010-021-04295-y. [PMID: 34973124] - Qi Sun, Fei Ye, Hao Liang, Hongbo Liu, Chunmei Li, Roujian Lu, Baoying Huang, Li Zhao, Wenjie Tan, Luhua Lai. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease.
Signal transduction and targeted therapy.
2021 05; 6(1):212. doi:
10.1038/s41392-021-00628-x. [PMID: 34052830] - Rosalba Siracusa, Ramona D'Amico, Marika Cordaro, Alessio Filippo Peritore, Tiziana Genovese, Enrico Gugliandolo, Rosalia Crupi, Daniela Impellizzeri, Salvatore Cuzzocrea, Roberta Fusco, Rosanna Di Paola. The Methyl Ester of 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid Reduces Endometrial Lesions Development by Modulating the NFkB and Nrf2 Pathways.
International journal of molecular sciences.
2021 Apr; 22(8):. doi:
10.3390/ijms22083991. [PMID: 33924360] - Yuanyuan Wang, Hao Ma, Jiaxuan Huang, Zhengguang Yao, Jianqiang Yu, Wannian Zhang, Lichao Zhang, Zhibin Wang, Chunlin Zhuang. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors.
European journal of medicinal chemistry.
2021 Feb; 212(?):113030. doi:
10.1016/j.ejmech.2020.113030. [PMID: 33248849] - Emine Kadıoğlu, Yasemin Tekşen, Cengiz Koçak, Fatma Emel Koçak. Beneficial effects of bardoxolone methyl, an Nrf2 activator, on crush-related acute kidney injury in rats.
European journal of trauma and emergency surgery : official publication of the European Trauma Society.
2021 Feb; 47(1):241-250. doi:
10.1007/s00068-019-01216-z. [PMID: 31471671] - Glenn M Chertow, Gerald B Appel, Sharon Andreoli, Sripal Bangalore, Geoffrey A Block, Arlene B Chapman, Melanie P Chin, Keisha L Gibson, Angie Goldsberry, Kazumoto Iijima, Lesley A Inker, Bertrand Knebelmann, Laura H Mariani, Colin J Meyer, Kandai Nozu, Megan O'Grady, Arnold L Silva, Peter Stenvinkel, Roser Torra, Bradley A Warady, Pablo E Pergola. Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.
American journal of nephrology.
2021; 52(3):180-189. doi:
10.1159/000513777. [PMID: 33789284] - James H Lewis, Michel Jadoul, Geoffrey A Block, Melanie P Chin, Deborah A Ferguson, Angie Goldsberry, Colin J Meyer, Megan O'Grady, Pablo E Pergola, Scott A Reisman, W Christian Wigley, Glenn M Chertow. Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD.
Clinical and translational science.
2021 01; 14(1):299-309. doi:
10.1111/cts.12868. [PMID: 32860734] - Hironori Kanda, Kengo Yamawaki. Bardoxolone methyl: drug development for diabetic kidney disease.
Clinical and experimental nephrology.
2020 Oct; 24(10):857-864. doi:
10.1007/s10157-020-01917-5. [PMID: 32594372] - Vicente Galiano, José A Encinar, José Villalaín. Location, Orientation and Aggregation of Bardoxolone-ME, CDDO-ME, in a Complex Phospholipid Bilayer Membrane.
The Journal of membrane biology.
2020 04; 253(2):115-128. doi:
10.1007/s00232-020-00106-5. [PMID: 31965219] - Chengcheng Gai, Mengyu Yu, Zihaoran Li, Yonghong Wang, Dejun Ding, Jie Zheng, Shijun Lv, Weifen Zhang, Wentong Li. Acetaminophen sensitizing erastin-induced ferroptosis via modulation of Nrf2/heme oxygenase-1 signaling pathway in non-small-cell lung cancer.
Journal of cellular physiology.
2020 04; 235(4):3329-3339. doi:
10.1002/jcp.29221. [PMID: 31541463] - Ewa Szczesny-Malysiak, Marta Stojak, Roberto Campagna, Marek Grosicki, Marek Jamrozik, Patrycja Kaczara, Stefan Chlopicki. Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium.
Oxidative medicine and cellular longevity.
2020; 2020(?):4678252. doi:
10.1155/2020/4678252. [PMID: 33123312] - Marie Ito, Masaomi Nangaku. Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?.
Kidney international.
2019 10; 96(4):823-825. doi:
10.1016/j.kint.2019.05.033. [PMID: 31543152] - Peter Rossing, Geoffrey A Block, Melanie P Chin, Angie Goldsberry, Hiddo J L Heerspink, Peter A McCullough, Colin J Meyer, David Packham, Pablo E Pergola, Bruce Spinowitz, Stuart M Sprague, David G Warnock, Glenn M Chertow. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Kidney international.
2019 10; 96(4):1030-1036. doi:
10.1016/j.kint.2019.04.027. [PMID: 31377056] - Min-Ju Kim, Hana Park, Seo-Hyeon Choi, Min-Jeong Kong, Ji-Eun Kim, Tae-Cheon Kang. CDDO-Me Attenuates Vasogenic Edema and Astroglial Death by Regulating NF-κB p65 Phosphorylations and Nrf2 Expression Following Status Epilepticus.
International journal of molecular sciences.
2019 Sep; 20(19):. doi:
10.3390/ijms20194862. [PMID: 31574956] - Sonia Celentano, Giovanna Capolongo, Rosa Maria Pollastro. [Bardoxolone: a new potential therapeutic agent in the treatment of autosomal dominant polycystic kidney disease?].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2019 Sep; 36(5):. doi:
NULL. [PMID: 31580543] - Min-Kyun Song, Jin-Hee Lee, In-Geun Ryoo, Sang-Hwan Lee, Sae-Kwang Ku, Mi-Kyoung Kwak. Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation.
Free radical biology & medicine.
2019 07; 138(?):33-42. doi:
10.1016/j.freeradbiomed.2019.04.033. [PMID: 31059771] - Richard Solomon. New Approach to Slowing the Progression of Chronic Kidney Disease.
Cardiorenal medicine.
2019; 9(5):334-336. doi:
10.1159/000502105. [PMID: 31357201] - Dana V Rizk, Arnold L Silva, Pablo E Pergola, Robert Toto, David G Warnock, Melanie P Chin, Angie Goldsberry, Megan O'Grady, Colin J Meyer, Peter A McCullough. Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Cardiorenal medicine.
2019; 9(5):316-325. doi:
10.1159/000500612. [PMID: 31170712] - Glenn M Chertow, Gerald B Appel, Geoffrey A Block, Melanie P Chin, Daniel W Coyne, Angie Goldsberry, Kamyar Kalantar-Zadeh, Colin J Meyer, Mark E Molitch, Pablo E Pergola, Philip Raskin, Arnold L Silva, Bruce Spinowitz, Stuart M Sprague, Peter Rossing. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Journal of diabetes and its complications.
2018 Dec; 32(12):1113-1117. doi:
10.1016/j.jdiacomp.2018.09.005. [PMID: 30318163] - Mikako Hisamichi, Atsuko Kamijo-Ikemori, Takeshi Sugaya, Seiko Hoshino, Kenjiro Kimura, Yugo Shibagaki. Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.
Hypertension research : official journal of the Japanese Society of Hypertension.
2018 Jan; 41(1):8-17. doi:
10.1038/hr.2017.83. [PMID: 28978980] - Melanie P Chin, George L Bakris, Geoffrey A Block, Glenn M Chertow, Angie Goldsberry, Lesley A Inker, Hiddo J L Heerspink, Megan O'Grady, Pablo E Pergola, Christoph Wanner, David G Warnock, Colin J Meyer. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
American journal of nephrology.
2018; 47(1):40-47. doi:
10.1159/000486398. [PMID: 29402767] - Zhangjian Huang, Yi Mou, Xiaojun Xu, Di Zhao, Yisheng Lai, Yuwen Xu, Cen Chen, Ping Li, Sixun Peng, Jide Tian, Yihua Zhang. Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy.
Journal of medicinal chemistry.
2017 11; 60(21):8847-8857. doi:
10.1021/acs.jmedchem.7b00971. [PMID: 28994286] - Aydın Güçlü, Cengiz Koçak, Fatma E Koçak, Raziye Akçılar, Yavuz Dodurga, Aydın Akçılar, Levent Elmas. MicroRNA-125b as a new potential biomarker on diagnosis of renal ischemia-reperfusion injury.
The Journal of surgical research.
2017 01; 207(?):241-248. doi:
10.1016/j.jss.2016.08.067. [PMID: 27979484] - Masahiro Nezu, Norio Suzuki, Masayuki Yamamoto. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
American journal of nephrology.
2017; 45(6):473-483. doi:
10.1159/000475890. [PMID: 28502971] - Dongjun Qin, Weiwei Wang, Hu Lei, Hao Luo, Haiyan Cai, Caixia Tang, Yunzhao Wu, Yingying Wang, Jin Jin, Weilie Xiao, Tongdan Wang, Chunmin Ma, Hanzhang Xu, Jinfu Zhang, Fenghou Gao, Ying-Li Wu. CDDO-Me reveals USP7 as a novel target in ovarian cancer cells.
Oncotarget.
2016 Nov; 7(47):77096-77109. doi:
10.18632/oncotarget.12801. [PMID: 27780924] - Matthew D Breyer, Katalin Susztak. Developing Treatments for Chronic Kidney Disease in the 21st Century.
Seminars in nephrology.
2016 11; 36(6):436-447. doi:
10.1016/j.semnephrol.2016.08.001. [PMID: 27987541] - Amandla Atilano-Roque, Lauren M Aleksunes, Melanie S Joy. Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injury.
Toxicology letters.
2016 Sep; 259(?):52-59. doi:
10.1016/j.toxlet.2016.07.021. [PMID: 27480280] - Cengiz Kocak, Fatma Emel Kocak, Raziye Akcilar, Zeynep Bayat, Bekir Aras, Mehmet Huseyin Metineren, Mehmet Yucel, Hasan Simsek. Effects of captopril, telmisartan and bardoxolone methyl (CDDO-Me) in ischemia-reperfusion-induced acute kidney injury in rats: an experimental comparative study.
Clinical and experimental pharmacology & physiology.
2016 Feb; 43(2):230-41. doi:
10.1111/1440-1681.12511. [PMID: 26515498] - Danielle Camer, Yinghua Yu, Alexander Szabo, Hongqin Wang, Chi H L Dinh, Xu-Feng Huang. Bardoxolone methyl prevents the development and progression of cardiac and renal pathophysiologies in mice fed a high-fat diet.
Chemico-biological interactions.
2016 Jan; 243(?):10-8. doi:
10.1016/j.cbi.2015.11.018. [PMID: 26612656] - Yan Zhao, Meirong Huo, Zhenghong Xu, Yuhua Wang, Leaf Huang. Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma.
Biomaterials.
2015 Nov; 68(?):54-66. doi:
10.1016/j.biomaterials.2015.07.053. [PMID: 26264646] - Danielle Camer, Yinghua Yu, Alexander Szabo, Chi H L Dinh, Hongqin Wang, Licai Cheng, Xu-Feng Huang. Bardoxolone methyl prevents insulin resistance and the development of hepatic steatosis in mice fed a high-fat diet.
Molecular and cellular endocrinology.
2015 Sep; 412(?):36-43. doi:
10.1016/j.mce.2015.05.018. [PMID: 26001833] - Chi H L Dinh, Alexander Szabo, Yinghua Yu, Danielle Camer, Qingsheng Zhang, Hongqin Wang, Xu-Feng Huang. Bardoxolone Methyl Prevents Fat Deposition and Inflammation in Brown Adipose Tissue and Enhances Sympathetic Activity in Mice Fed a High-Fat Diet.
Nutrients.
2015 Jun; 7(6):4705-23. doi:
10.3390/nu7064705. [PMID: 26066016] - Melanie P Chin, Danielle Wrolstad, George L Bakris, Glenn M Chertow, Dick de Zeeuw, Angie Goldsberry, Peter G Linde, Peter A McCullough, John J McMurray, Janet Wittes, Colin J Meyer. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Journal of cardiac failure.
2014 Dec; 20(12):953-8. doi:
10.1016/j.cardfail.2014.10.001. [PMID: 25307295] - Tianfu Wu, Yujin Ye, So-Youn Min, Jiankun Zhu, Elhaum Khobahy, Jason Zhou, Mei Yan, Sriram Hemachandran, Simanta Pathak, Xin J Zhou, Michael Andreeff, Chandra Mohan. Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid.
Arthritis & rheumatology (Hoboken, N.J.).
2014 Nov; 66(11):3129-39. doi:
10.1002/art.38782. [PMID: 25047252] - Joanne Walsh, Rosalind E Jenkins, Michael Wong, Adedamola Olayanju, Helen Powell, Ian Copple, Paul M O'Neill, Christopher E P Goldring, Neil R Kitteringham, B Kevin Park. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.
Journal of proteomics.
2014 Aug; 108(?):171-87. doi:
10.1016/j.jprot.2014.05.007. [PMID: 24859727] - Ian M Copple, Luke M Shelton, Joanne Walsh, Denise V Kratschmar, Adam Lister, Alex Odermatt, Christopher E Goldring, Albena T Dinkova-Kostova, Tadashi Honda, B Kevin Park. Chemical tuning enhances both potency toward nrf2 and in vitro therapeutic index of triterpenoids.
Toxicological sciences : an official journal of the Society of Toxicology.
2014 Aug; 140(2):462-9. doi:
10.1093/toxsci/kfu080. [PMID: 24798383] - Nathan S Teuscher, Richard J Kelley, Emily O Dumas, Cheri Enders Klein, Walid M Awni, Colin J Meyer. A food effect study and dose proportionality study to assess the pharmacokinetics and safety of bardoxolone methyl in healthy volunteers.
Clinical pharmacology in drug development.
2014 07; 3(4):314-20. doi:
10.1002/cpdd.74. [PMID: 27128838] - Sih Min Tan, Judy B de Haan. Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much?.
Redox report : communications in free radical research.
2014 May; 19(3):107-17. doi:
10.1179/1351000214y.0000000087. [PMID: 24559141] - Juan Wu, Xinhui Liu, Jinjin Fan, Wenfang Chen, Juan Wang, Youjia Zeng, Xiaorang Feng, Xueqing Yu, Xiao Yang. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.
Toxicology.
2014 Apr; 318(?):22-31. doi:
10.1016/j.tox.2014.01.008. [PMID: 24530882] - Daniela Impellizzeri, Emanuela Esposito, James Attley, Salvatore Cuzzocrea. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).
Pharmacological research.
2014 Mar; 81(?):91-102. doi:
10.1016/j.phrs.2014.02.007. [PMID: 24602801] - Yan-Yang Wang, Hong Zhe, Ren Zhao. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment.
Molecular cancer.
2014 Feb; 13(?):30. doi:
10.1186/1476-4598-13-30. [PMID: 24552536] - Danielle Camer, Xu-Feng Huang. The endothelin pathway: a protective or detrimental target of bardoxolone methyl on cardiac function in patients with advanced chronic kidney disease?.
American journal of nephrology.
2014; 40(3):288-90. doi:
10.1159/000368563. [PMID: 25323320] - Yan-Yang Wang, Yin-Xue Yang, Hong Zhe, Zhi-Xu He, Shu-Feng Zhou. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
Drug design, development and therapy.
2014; 8(?):2075-88. doi:
10.2147/dddt.s68872. [PMID: 25364233] - Melanie P Chin, Scott A Reisman, George L Bakris, Megan O'Grady, Peter G Linde, Peter A McCullough, David Packham, Nosratola D Vaziri, Keith W Ward, David G Warnock, Colin J Meyer. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
American journal of nephrology.
2014; 39(6):499-508. doi:
10.1159/000362906. [PMID: 24903467] - Jonathan Himmelfarb, Katherine R Tuttle. New therapies for diabetic kidney disease.
The New England journal of medicine.
2013 Dec; 369(26):2549-50. doi:
10.1056/nejme1313104. [PMID: 24206460] - Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J Lambers Heerspink, John J McMurray, Colin J Meyer, Hans-Henrik Parving, Giuseppe Remuzzi, Robert D Toto, Nosratola D Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M Chertow. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
The New England journal of medicine.
2013 12; 369(26):2492-503. doi:
10.1056/nejmoa1306033. [PMID: 24206459] - Hiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, Paul Audhya, George L Bakris, Angie Goldsberry, Melissa Krauth, Peter Linde, John J McMurray, Colin J Meyer, Hans-Henrik Parving, Giuseppe Remuzzi, Heidi Christ-Schmidt, Robert D Toto, Nosratola D Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Dick de Zeeuw. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2013 Nov; 28(11):2841-50. doi:
10.1093/ndt/gft445. [PMID: 24169612] - Donna D Zhang. Bardoxolone brings Nrf2-based therapies to light.
Antioxidants & redox signaling.
2013 Aug; 19(5):517-8. doi:
10.1089/ars.2012.5118. [PMID: 23227819] - Melanie Chin, Chun-Yue Ivy Lee, Jen-Chieh Chuang, Ron Bumeister, W Christian Wigley, Stephen T Sonis, Keith W Ward, Colin Meyer. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.
American journal of physiology. Renal physiology.
2013 Jun; 304(12):F1438-46. doi:
10.1152/ajprenal.00387.2012. [PMID: 23594825] - Stacey Ruiz, Pablo E Pergola, Richard A Zager, Nosratola D Vaziri. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease.
Kidney international.
2013 Jun; 83(6):1029-41. doi:
10.1038/ki.2012.439. [PMID: 23325084] - Liangfeng Fu, Gordon W Gribble. Efficient and scalable synthesis of bardoxolone methyl (cddo-methyl ester).
Organic letters.
2013 Apr; 15(7):1622-5. doi:
10.1021/ol400399x. [PMID: 23530743] - Hideyuki Saito. Toxico-pharmacological perspective of the Nrf2-Keap1 defense system against oxidative stress in kidney diseases.
Biochemical pharmacology.
2013 Apr; 85(7):865-72. doi:
10.1016/j.bcp.2013.01.006. [PMID: 23333765] - Carla Zoja, Daniela Corna, Valeria Nava, Monica Locatelli, Mauro Abbate, Flavio Gaspari, Fabiola Carrara, Fabio Sangalli, Giuseppe Remuzzi, Ariela Benigni. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.
American journal of physiology. Renal physiology.
2013 Mar; 304(6):F808-19. doi:
10.1152/ajprenal.00376.2012. [PMID: 23136004] - Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, Paul Audhya, George L Bakris, Melanie Chin, Melissa Krauth, Hiddo J Lambers Heerspink, Colin J Meyer, John J McMurray, Hans-Henrik Parving, Pablo E Pergola, Giuseppe Remuzzi, Robert D Toto, Nosratola D Vaziri, Christoph Wanner, David G Warnock, Janet Wittes, Glenn M Chertow. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
American journal of nephrology.
2013; 37(3):212-22. doi:
10.1159/000346948. [PMID: 23467003] - Yong Qin, Wuguo Deng, Suhendan Ekmekcioglu, Elizabeth A Grimm. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening.
Pigment cell & melanoma research.
2013 Jan; 26(1):97-112. doi:
10.1111/pcmr.12031. [PMID: 23020131] - Eleanor D Lederer, Jon B Klein. New treatments for CKD--new insights into pathogenesis.
Journal of the American Society of Nephrology : JASN.
2012 Oct; 23(10):1601-3. doi:
10.1681/asn.2012080842. [PMID: 22975668] - Scott A Reisman, Glenn M Chertow, Sudarshan Hebbar, Nosratola D Vaziri, Keith W Ward, Colin J Meyer. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney.
Journal of the American Society of Nephrology : JASN.
2012 Oct; 23(10):1663-73. doi:
10.1681/asn.2012050457. [PMID: 22859857] - Merlin Thomas. A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy.
Expert opinion on drug metabolism & toxicology.
2012 Aug; 8(8):1015-22. doi:
10.1517/17425255.2012.697152. [PMID: 22747345] - David S Hong, Razelle Kurzrock, Jeffrey G Supko, Xiaoying He, Aung Naing, Jennifer Wheler, Donald Lawrence, Joseph Paul Eder, Colin J Meyer, Deborah A Ferguson, James Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Kufe, Hillard Lazarus, Geoffrey I Shapiro, Bruce J Dezube. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2012 Jun; 18(12):3396-406. doi:
10.1158/1078-0432.ccr-11-2703. [PMID: 22634319] - Jacob Pollier, Alain Goossens. Oleanolic acid.
Phytochemistry.
2012 May; 77(?):10-5. doi:
10.1016/j.phytochem.2011.12.022. [PMID: 22377690] - Daniel Merk, Manfred Schubert-Zsilavecz. New hope or drawbacks: will chronic kidney disease be treatable with small molecules in the near future?.
Future medicinal chemistry.
2012 Mar; 4(3):269-71. doi:
10.4155/fmc.11.182. [PMID: 22393934] - Jeffrey M Turner, Carolyn Bauer, Matthew K Abramowitz, Michal L Melamed, Thomas H Hostetter. Treatment of chronic kidney disease.
Kidney international.
2012 Feb; 81(4):351-62. doi:
10.1038/ki.2011.380. [PMID: 22166846] - Peter A McCullough, Sajid Ali. Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl.
Drug design, development and therapy.
2012; 6(?):141-9. doi:
10.2147/dddt.s26714. [PMID: 22787387] - Jean-Jacques Boffa, Jean-Claude Dussaule, Pierre Ronco, Christos Chatziantoniou. [Chronic kidney disease, new therapeutic approaches].
La Revue du praticien.
2012 Jan; 62(1):72-5. doi:
NULL. [PMID: 22335071] - David G Warnock, Sudarshan Hebbar, Joanne Bargman, John Burkart, Simon Davies, Frederic O Finkelstein, Rajnish Mehrotra, Claudio Ronco, Isaac Teitelbaum, Kingsley Urakpo, Glenn M Chertow. Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis.
Contributions to nephrology.
2012; 178(?):157-163. doi:
10.1159/000337837. [PMID: 22652731] - Merlin C Thomas. Bardoxolone: augmenting the Yin in chronic kidney disease.
Diabetes & vascular disease research.
2011 Oct; 8(4):303-4. doi:
10.1177/1479164111421034. [PMID: 21933845] - Merlin C Thomas, Mark E Cooper. Diabetes: bardoxolone improves kidney function in type 2 diabetes.
Nature reviews. Nephrology.
2011 Aug; 7(10):552-3. doi:
10.1038/nrneph.2011.114. [PMID: 21862993] - Pablo E Pergola, Philip Raskin, Robert D Toto, Colin J Meyer, J Warren Huff, Eric B Grossman, Melissa Krauth, Stacey Ruiz, Paul Audhya, Heidi Christ-Schmidt, Janet Wittes, David G Warnock. Bardoxolone methyl and kidney function in CKD with type 2 diabetes.
The New England journal of medicine.
2011 Jul; 365(4):327-36. doi:
10.1056/nejmoa1105351. [PMID: 21699484] - Qing Qing Wu, Yanxia Wang, Martin Senitko, Colin Meyer, W Christian Wigley, Deborah A Ferguson, Eric Grossman, Jianlin Chen, Xin J Zhou, John Hartono, Pamela Winterberg, Bo Chen, Anapam Agarwal, Christopher Y Lu. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.
American journal of physiology. Renal physiology.
2011 May; 300(5):F1180-92. doi:
10.1152/ajprenal.00353.2010. [PMID: 21289052] - Tadashi Honda, Hidenori Yoshizawa, Chitra Sundararajan, Emilie David, Marc J Lajoie, Frank G Favaloro, Tomasz Janosik, Xiaobo Su, Yukiko Honda, Bill D Roebuck, Gordon W Gribble. Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
Journal of medicinal chemistry.
2011 Mar; 54(6):1762-78. doi:
10.1021/jm101445p. [PMID: 21361338] - Ankur Gupta, Ambar Khaira. Bardoxolone methyl: a targeted antioxidant.
Renal failure.
2011; 33(10):1051. doi:
10.3109/0886022x.2011.618970. [PMID: 22013943] - Pablo E Pergola, Melissa Krauth, J Warren Huff, Deborah A Ferguson, Stacey Ruiz, Colin J Meyer, David G Warnock. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD.
American journal of nephrology.
2011; 33(5):469-76. doi:
10.1159/000327599. [PMID: 21508635] - Pradip K Saha, Vasumathi T Reddy, Marina Konopleva, Michael Andreeff, Lawrence Chan. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice.
The Journal of biological chemistry.
2010 Dec; 285(52):40581-92. doi:
10.1074/jbc.m110.176545. [PMID: 20956520]